Azienda Socio Sanitaria Territoriale Della Valtellina E Dell Alto Lario
- Address
- lock Available on a paid plan
Neoplasms and Respiratory Tract Diseases
At Azienda Socio Sanitaria Territoriale Della Valtellina E Dell Alto Lario, the Radiotherapy department is involved in clinical research focused on lung cancer, colorectal cancer, breast cancer, and other solid tumors. These studies are designed to evaluate new treatment strategies, compare effectiveness between therapies, and support better outcomes for patients with advanced or early-stage disease.
- Research in non-small cell lung cancer and advanced metastatic lung cancer aims to assess treatment benefit and disease control.
- Trials in HER2-positive breast cancer and HER2-positive colorectal cancer are exploring improved cancer therapy options.
- Studies in rectal cancer and prostate cancer are testing treatment approaches that may improve tumor response and long-term control.
Overall, the site contributes to oncology research that combines radiation oncology with systemic therapies to refine care for patients with solid tumors.
Hemic and Lymphatic Diseases and Cardiovascular Diseases
The clinical trial portfolio also includes work in blood cancers and vascular disease, reflecting a broad research interest beyond solid tumors. At this hospital, investigators are studying ways to improve treatment effectiveness, reduce relapse risk, and make care safer for patients.
- Research in follicular lymphoma is examining whether treatment can be tailored while maintaining strong disease control.
- A study in venous thromboembolism is focused on preventing recurrence after a first clotting event in older patients.
- These projects aim to balance efficacy and safety in conditions where long-term management is especially important.
This work highlights the site’s interest in both hematology and thrombosis prevention, with a clear focus on practical patient benefit.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Fondazione Italiana Linfomi Ets1active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fondazione Italiana Linfomi Ets2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Socio Sanitaria Territoriale Della Valtellina E Dell Alto Lario
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 2 | Unknown | 2022-02-01 | 2022-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.